loader image

Backing science, engineering and technology innovation that positively impacts our world.

Founded 2014 | St Andrews, Scotland

Eos exists to support founders. 

Innovation in science, engineering and technology is key to improving quality of life, making agriculture and aquaculture more sustainable, mitigating climate change, finding new energy solutions and much more.
Commercial returns as well as positive impact are the key metrics for all of our work. By addressing key issues facing society, you are by definition addressing markets of scale.

Deep roots in Scotland, with a global perspective.

Insert a quote here from one of the team members that relates to this section maybe, or metric values perhaps?

Team member, Title

Connections with world-class research universities at home and across the UK remains crucial for our work, as well as networks into industry.  Finding, understanding, and scaling innovation is not something that can be done at arm’s length and because all of our investments have global application, we spend an equal amount of time supporting them to scale into larger commercial markets.

Most funders are not willing to back nascent ventures until they have a financial track record, because they don’t understand the potential and IP underlying knowledge intensive companies. Eos does.  We firmly believe that commercial returns should be commensurate with early-stage risk, and to realise these returns you need sector specialism and the capacity to work closely with portfolio companies.

Trust, hard work and discretion are important values at Eos.  Everyone who is a part of the Eos eco-system has a level of altruistic motivation, a fascination in the impact these businesses can have within industry and within society.  Commercial returns are clearly also important and so knowing that Eos has the depth of knowledge, network, and work ethic to support companies is of paramount importance. 

We welcome new founders and new investors who share the belief that scientific, engineering and technology innovations are the best way to balance commercial success whilst also having positive impact on major global issues.

The Eos team is made up of founders, scientists, record breakers, industry leaders, and government advisors.

Executive Team

profile

Andrew McNeill

Managing Partner

profile

Mark Beaumont

Partner, Investor Relationships

Andrew Durkie

Partner - Investments

Calum Keddie

Investment Executive

profile

Kevin Grainger

Founder & Syndicate Chairman

profile

Ana Stewart

Partner

profile

Chris Brinsmead

Partner

profile

Rick Clark

Partner

Valerie Joliffe

Fund Manager

Andy Lothian

Growth Advisor

Sandy Kennedy

Growth Advisor

Ben Hasselgren

I.T and Design

Eos invests through an Angel Syndicate, an EIS Innovation Fund & Venture Partnerships.

We also have Scottish Enterprise co-investment status.  The breadth of this co-investment is important for scaling, balancing of risk and also to build relationships with people and organisations who can understand and help our businesses grow over the long term.

A growing & thriving portfolio

Meet our inspiring founders. Companies are defined by people and their performance.

Ishani Malhotra

Carcinotech is a MedTech company manufacturing 3D printed mini tumours developed from patient-specific cancer stem cells, primary cells and established cell lines.
Eos first invested: April, 2022

Clare Waring

Europes first cancer drug accelerator. Finding assets, creating spin-outs, commercialising cancer therapies.
Eos first invested: June, 2020

Rotimi Alabi

Lab-on-a-chip’ technology that delivers oil analysis 1000x faster and 10x cheaper than the current ‘send the sample to laboratory approach.
Eos first invested: December, 2020

Richard Kuo

Specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.
Eos first invested: July, 2021

Gavin Munro

Formed in 2014 to offer Adjusta-Cone® as the world’s first fully adjustable differential pressure cone meter for natural gas.
Eos first invested: January, 2020

Joel Watt

Connects seafood buyers and suppliers, giving them the right tools to trade efficiently, negotiate prices and process deliveries across Europe – all in real-time, 24/7.
Eos first invested: October, 2019

Dr Mark Hegarty

Offers a revolutionary spectroscopic liquid biopsy with artificial intelligence for the early detection of cancer and other diseases.
Eos first invested: February, 2019

Dr Dave Hughes

An award winning Scottish sensors company utilising thin-film processes to eliminate conventional limitations in ultrasound sensors.
Eos first invested: April, 2018

Jim Laird

ABUNDA mycoprotein is a fermented food ingredient, rich in protein and fibre. Naturally fortified in B12, zinc and iron. ABUNDA is highly nutritious.
Eos first invested: June, 2017

Prof. Ian A. Johnston

A provider of specialist genetics and breeding management services to the aquaculture industry.
Eos first invested: March, 2016

Shahida Imani

With minimal set-up and an intuitive web browser interface, their femtosecond lasers and picosecond OPOs, enable the scientific community and industrial partners to push boundaries and discover more.
Eos first invested: December, 2015

Paul Robert Cary

AI and Content Automation to help companies achieve incredible marketing results through Digital Video.
Eos first invested: December, 2015

Prof. W. H. Stimson

An early stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for Virology, Cancer, Atopic Dermatitis and Psoriasis.
Eos first invested: July, 2015

News

SEIS limit increased to £250k

October 3, 2022

Read more

Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets

September 6, 2022

Read more

Cleantech Startup Penrhos Bio Raises £1m with Support from Eos

September 5, 2022

Read more

Get in touch

General enquiries

Address

​Eos Advisory LLP,
Kinburn Castle,
Doubledykes Road, St Andrews,
KY16 9DR

Emails

Angel Syndicate

A Syndicate of like-minded entrepreneurs was how Eos started in 2014 and it has since grown to a private members group of around 60 individuals who typically meet 4 times a year either in St Andrews or online to consider investment opportunities that the Eos executive has pre-screened. Members are usually presented with 1-2 investment opportunities per meeting. These have been carefully selected from a large pool of applications, not only for the strength of the underlying science or technology, but also for their market potential, management team and exit potential. The investment opportunities are predominantly Scottish based businesses, often spin-outs from Universities and they will always be early stage, generally pre-revenue.

Innovation Fund

The Eos EIS Innovation Fund backs businesses in the same impact areas as the Syndicate and has the ability to co-invest or invest separately. The Fund is designed for investors and financial advisors who do not have the desire, the time or the ability to attend pitch meetings and make direct investment decisions as syndicate members.  Funds are diversified into a portfolio of at least 5 businesses, and recommendations are made by the Investment Committee, made up of the Eos partners, with the final investment decision held by our Fund Manager. 
 

The businesses that we back all aim to have a positive impact on the world around us, whilst also delivering a commercial return. By addressing global challenges, we are backing Scottish innovation that has a significant market opportunity.  Eos, alongside our network of advisors and investment directors, works with innovators to build the foundational years of companies.

Venture Partners

Eos has extensive access to the Scottish start-up market and the ability to lead due diligence and transactions on deep science and technology. We look for Venture Partners who have a range of complimentary strengths, the ability to invest at Series A and trade connections and experience.

Each Venture Partnership is unique and based on the overlap of interests. We are seeing particular growth in life science and climate change opportunities, and are actively looking for new UK and international Venture Partnerships in these areas, whilst continuing to invest across our four impact areas.

Latest news

SEIS limit increased to £250k
03 October 2022
Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets
06 September 2022

This website uses cookies to ensure you get the best experience on our website. By continuing to browse on this website, you accept the use of cookies for the above purposes.